PMID- 17934850
OWN - NLM
STAT- MEDLINE
DCOM- 20080617
LR  - 20220716
IS  - 0163-2116 (Print)
IS  - 0163-2116 (Linking)
VI  - 53
IP  - 5
DP  - 2008 May
TI  - Angiotensin II type 1 receptor antagonist suppress angiogenesis and growth of 
      gastric cancer xenografts.
PG  - 1206-10
AB  - Angiotensin II (Ang II) has been reported to promote tumor progression, tumor 
      growth and angiogenesis in many cancers. We previously observed that angiotensin 
      II type 1 receptors (AT1R) were upregulated in human gastric cancer and may be 
      involved in the progression of gastric cancer. We studied the effects of AT1R 
      antagonist on angiogenesis and growth in gastric cancer xenografts to observe the 
      mechanism action of AT1R in the gastric cancer. The results showed that the 
      growth of gastric cancer cells was significantly suppressed by treatment with 
      AT1R antagonist. In vivo, TCV-116, at doses of both 2 and 5 mg/kg/day, 
      significantly suppressed tumor growth in mice (47.3 and 70.2%). Microvessel 
      density was significantly decreased by TCV-116 (3.4 +/- 0.9 and 2.8 +/- 0.5 per 
      field) compared with the control group (12.9 +/- 1.1 per field), and VEGF 
      expression was significantly suppressed by AT1R antagonist. These results 
      demonstrate that AT1R plays an important role in the progression of gastric 
      cancer. Suppression tumor angiogenesis could be one of the mechanisms by which 
      AT1R antagonist suppresses the growth of gastric cancer. These findings also 
      provide a theoretical basis for the future clinical application of AT1R 
      antagonist against gastric cancer.
FAU - Huang, Wei
AU  - Huang W
AD  - Department of Gastroenterology, Ruijin Hospital, School of Medicine, Jiaotong 
      University, Shanghai, China.
FAU - Wu, Yun-Lin
AU  - Wu YL
FAU - Zhong, Jie
AU  - Zhong J
FAU - Jiang, Feng-Xiang
AU  - Jiang FX
FAU - Tian, Xiang-Long
AU  - Tian XL
FAU - Yu, Li-Fen
AU  - Yu LF
LA  - eng
PT  - Journal Article
DEP - 20071013
PL  - United States
TA  - Dig Dis Sci
JT  - Digestive diseases and sciences
JID - 7902782
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Benzimidazoles)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Tetrazoles)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - R85M2X0D68 (candesartan cilexetil)
SB  - IM
MH  - Administration, Oral
MH  - Analysis of Variance
MH  - Angiotensin II Type 1 Receptor Blockers/administration & dosage/*pharmacology
MH  - Animals
MH  - Benzimidazoles/administration & dosage/*pharmacology
MH  - Biphenyl Compounds/administration & dosage/*pharmacology
MH  - Cell Line, Tumor
MH  - Humans
MH  - Immunohistochemistry
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - Neovascularization, Pathologic/metabolism/*prevention & control
MH  - Statistics, Nonparametric
MH  - Stomach Neoplasms/blood supply/*drug therapy/pathology
MH  - Tetrazoles/administration & dosage/*pharmacology
MH  - Transplantation, Heterologous
MH  - Vascular Endothelial Growth Factor A/metabolism
EDAT- 2007/10/16 09:00
MHDA- 2008/06/18 09:00
CRDT- 2007/10/16 09:00
PHST- 2007/04/30 00:00 [received]
PHST- 2007/08/28 00:00 [accepted]
PHST- 2007/10/16 09:00 [pubmed]
PHST- 2008/06/18 09:00 [medline]
PHST- 2007/10/16 09:00 [entrez]
AID - 10.1007/s10620-007-0009-9 [doi]
PST - ppublish
SO  - Dig Dis Sci. 2008 May;53(5):1206-10. doi: 10.1007/s10620-007-0009-9. Epub 2007 
      Oct 13.